Regeneron to Highlight Scientific Advancements Across
Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse...
Source: globenewswire.com
Page 3 - Refractory Multiple News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Refractory Multiple Today - Breaking & Trending Today
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations...
Source: marketscreener.com
Elranatamab Approaches EU Approval for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of elranatamab-bccm for the treatment of adult patients with relapsed/refractory multiple myeloma who were previously treated with 3 or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and who experienced disease progression on their last therapy.
Source: onclive.com
Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
Source: prnewswire.com
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
/PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody...
Source: prnewswire.com